Multicenter phase ii study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG)

Table 2 Risk factors for acute graft-versus-host disease determined by univariate analysis

Variable	N	Grade 2–4 aGVHD			Grade 3–4 aGVHD
Variable	N	HR	95% CI	P	HR	95% CI	P
Age for recipients,years
<40	305	1.00			1.00
≥40	189	1.62	1.11-2.36	0.013	1.14	0.64-2.06	0.656
Age for donor, years
<40	306	1.00			1.00
≥40	188	1.50	1.01-2.24	0.046	0.90	0.48-1.68	0.732
Age for donor and recipients, years
Recipients < 40 and donor < 40	260	1.00			1.00
Recipients < 40 and donor ≥ 40	56	1.08	0.54-2.16	0.821	0.58	0.17-1.92	0.370
Recipients ≥ 40 and donor < 40	46	1.23	0.60-2.52	0.578	0.97	0.34-2.80	0.953
Recipients ≥ 40 and donor ≥ 40	132	1.77	1.13-2.77	0.013	1.03	0.51-2.08	0.929
Donor-recipient gender
Other	354	1.00			1.00
Female → Male	140	1.13	0.74-1.71	0.574	1.19	0.64-2.21	0.575
Stem cell source
BM + PB	240	1.00			1.00
PB	254	1.17	0.80-1.70	0.430	1.54	0.85-2.78	0.155
Leukemia type
AL	305	1.00			1.00
CML	155	0.71	0.46-1.12	0.142	0.76	0.39-1.47	0.411
Conditioning regimen
BuCy	341	1.00			1.00
TBICy	24	1.75	0.80-3.81	0.160	2.20	0.66-7.36	0.199
BuFlu	128	1.63	1.08-2.46	0.020	2.86	1.57-5.20	0.001
Donor-recipient blood type
Match	306	1.00			1.00
Mis-match	188	0.93	0.62-1.40	0.730	0.85	0.47-1.58	0.611
Disease stage
Non-advanced	429	1.00			1.00
Advanced	65	1.67	1.01-2.77	0.047	3.17	1.67-6.03	0.000
MMF dose
0.5 g/d	128	1.00			1.00
1.0 g/d	366	1.39	0.87-2.22	0.168	1.01	0.52-1.94	0.983

aGVHD, acute graft-versus-host disease; AL, acute leukemia; CML, chronic myelogenous leukemia; BM, bone marrow; BP, peripheral blood; TBI, total body irradiation; Cy, cyclophosphamide; Bu, busulfan; MMF, mycophenolate mofetil; Flu, fludarabin; Non-advanced stage, including acute leukemia (AL) in CR, CML in CP and AP, MDS-RAEB; Advanced stage, including AL in NR and CML in BC.

ISSN: 1756-8722